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and HydroxyChloroquine in Hospitalised
Patients With COVID-19 (ProPAC-COVID):
A structured summary of a study protocol
for a randomised controlled trial
Pradeesh Sivapalan1,2, Charlotte Suppli Ulrik3, Rasmus Dahlin Bojesen4, Therese Sophie Lapperre5,
Josefin Viktoria Eklöf1, Kjell Erik Julius Håkansson3, Andrea Browatzki6, Casper Tidemansen3, Jon Torgny Wilcke1,
Julie Janner3, Vibeke Gottlieb1, Howraman Meteran1, Celeste Porsbjerg5, Birgitte Lindegaard Madsen6,
Mia Moberg3, Lars Pedersen5, Thomas Lars Benfield7, Jens Dilling Lundgren8, Filip Krag Knop9,
Tor Biering-Sørensen10, Muzhda Ghanizada5, Tine Peick Sonne1, Uffe Christian Steinholtz Bødtger2,11,12,
Sidse Graff Jensen1, Daniel Bech Rasmussen11, Eva Brøndum3, Oliver Djurhuus Tupper3,
Susanne Wiemann Sørensen3, Gitte Alstrup11, Christian Borbjerg Laursen13, Ulla Weinrich Møller14,
Asger Sverrild5 and Jens-Ulrik Stæhr Jensen1*Abstract
Objectives: The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the
antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and
pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19
(measured as "days alive and out of hospital" as the primary outcome), reduce the risk of non- invasive ventilation,
treatment in the intensive care unit and death.
Trial design: This is a multi-centre, randomised, Placebo-controlled, 2-arm ratio 1:1, parallel group double-blind
study.
Participants: 226 participants are recruited at the trial sites/hospitals, where the study will take place in Denmark:
Aalborg, Bispebjerg, Gentofte, Herlev, Hillerød, Hvidovre, Odense and Slagelse hospitals.
Inclusion criteria:
• Patient admitted to Danish emergency departments, respiratory medicine departments or internal medicine
departments
• Age≥ 18 years
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• Hospitalized ≤48 hours
• Positive COVID-19 test / diagnosis during the hospitalization (confirmed).
• Men or non-fertile women. Fertile women* must not be pregnant, i.e. negative pregnancy test must be available
at inclusion
• Informed consent signed by the patient
*Defined as after menarche and until postmenopausal (no menstruation for 12 months)
Exclusion criteria:
• At the time of recruitment, the patient uses >5 LO2/min (equivalent to 40% FiO2 if measured)
• Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or
4-aminoquinoline derivatives
• Neurogenic hearing loss
• Psoriasis
• Retinopathy
• Maculopathy
• Visual field changes
• Breastfeeding
• Severe liver diseases other than amoebiasis (INR> 1.5 spontaneously)
• Severe gastrointestinal, neurological and hematological disorders (investigator-assessed)
• eGFR <45 ml/min/1.73 m2
• Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval (QTc (f) of> 480/470 ms).
• Myasthenia gravis
• Treatment with digoxin*
• Glucose-6-phosphate dehydrogenase deficiency
• Porphyria
• Hypoglycaemia (Blood glucose at any time since hospitalization of <3.0 mmol/L)
• Severe mental illness which significantly impedes cooperation
• Severe linguistic problems that significantly hinder cooperation
• Treatment with ergot alkaloids
*The patient must not be treated with digoxin for the duration of the intervention. For atrial fibrillation/flutter,
select according to the Cardiovascular National Treatment Guide (NBV): Calcium antagonist, Beta blocker, direct
current (DC) conversion or amiodarone. In case of urgent need for digoxin treatment (contraindication for the
aforementioned equal alternatives), the test drug should be paused, and ECG should be taken daily.
Intervention and comparator: Control group:
The control group will receive the standard treatment + placebo for both types of intervention medication at all
times. If part or all the intervention therapy being investigated becomes standard treatment during the study, this
may also be offered to the control group.
Intervention group:
The patients in the intervention group will also receive standard care. Immediately after randomisation to the
intervention group, the patient will begin treatment with:
Azithromycin:
Day 1-3: 500 mg x 1
Day 4-15: 250 mg x 1
If the patient is unable to take the medication orally by themselves, the medication will, if possible, be administered
by either stomach-feeding tube, or alternatively, temporary be changed to clarithromycin 500 mg x 2 (this only in
agreement with either study coordinator Pradeesh Sivapalan or principal investigator Jens-Ulrik Stæhr Jensen). This
will also be done in the control group if necessary. The patient will switch back to azithromycin when possible.
Hydroxychloroquine:
Furthermore, the patient will be treated with hydroxychloroquine as follows:
Day 1-15: 200 mg x 2
(Continued on next page)
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Main outcomes: • Number of days alive and discharged from hospital within 14 days (summarises both whether
the patient is alive and discharged from hospital) ("Days alive and out of hospital")
Randomisation: The sponsor (Chronic Obstructive Pulmonary Disease Trial Network, COP:TRIN) generates a
randomisation sequence. Randomisation will be in blocks of unknown size and the final allocation will be via an
encrypted website (REDCap). There will be stratification for age (>70 years vs. <=70 years), site of recruitment and
whether the patient has any of the following chronic lung diseases: COPD, asthma, bronchiectasis, interstitial lung
disease (Yes vs. No).
Blinding (masking): Participants and study personnel will both be blinded, i.e. neither will know which group the
participant is allocated to.
Numbers to be randomised (sample size): This study requires 226 patients randomised 1:1 with 113 in each
group.
Trial Status: Protocol version 1.8, from April 16, 2020. Recruitment is ongoing (first patient recruited April 6, 2020;
final patient expected to be recruited October 31, 2020).
Trial registration: ClinicalTrials.gov Identifier: NCT04322396 (registered March 26, 2020)
Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter
serves as a summary of the key elements of the full protocol.
The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for
Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
Keywords: COVID-19, Randomised controlled trial, protocol, azithromycin, hydroxychloroquine, respiratory
infectionsSupplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04409-9.
Additional file 1. Full study protocol.
Additional file 2. SPIRIT checklist.
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